265644-03-9

Usage

Uses

Used in Pharmaceutical Drug Synthesis:
2,5-difluorobenzohydrazide is used as a key intermediate in the synthesis of pharmaceutical drugs for its ability to enhance the biological activity of the resulting compounds. The presence of fluorine atoms on the benzene ring can improve the pharmacokinetic and pharmacodynamic properties of the drugs, making them more effective and suitable for various therapeutic applications.
Used in Agrochemical Development:
In the agrochemical industry, 2,5-difluorobenzohydrazide is utilized as a building block for the development of new agrochemicals. Its reactivity and potential to form various derivatives contribute to the creation of innovative products with improved performance and selectivity in crop protection and pest management.
Used as a Corrosion Inhibitor:
2,5-difluorobenzohydrazide has shown potential as a corrosion inhibitor, making it useful in industries where metal protection is crucial. Its application can help prevent the degradation of metal surfaces, thereby extending the service life of equipment and infrastructure.
Used in Materials Science:
In the field of materials science, 2,5-difluorobenzohydrazide is employed for its potential to contribute to the development of new materials with unique properties. Its incorporation into various systems can lead to advancements in areas such as polymer science, nanotechnology, and material coatings.

Upstream product

• 708-25-8 ethyl 2,5-difluorobenzoate 
• 2991-28-8 2,5-difluorobenzoic acid 
• 1079843-62-1 C₁₂H₁₄F₂N₂O₃ 

Downstream Products

• 1079843-41-6 {4-[(2,5-difluorobenzoyl)hydrazono]-4-phenylbutyl}-carbamic acid tert-butyl ester 
• 1079843-63-2 2,5-difluorobenzoic acid [4-(tert-butyldimethylsilanyloxy)-1-phenylbutylidene]-hydrazide 
• 1243273-14-4 3-(2,5-difluorophenyl)-6-(1H-indol-5-yl)-1,2,4-triazalo[4,3-b]pyridazine 
• 1459280-41-1 (E)-N’-(3-(trifluoromethyl)benzylidene)-2,5-difluorobenzohydrazide 
• 1459280-42-2 (E)-N’-(4-(trifluoromethyl)benzylidene)-2,5-difluorobenzohydrazide 
• 1459280-43-3 (E)-N’-(4-(trifluoromethoxy)benzylidene)-2,5-difluorobenzohydrazide 
• 1459280-45-5 (E)-N’-(2,4-difluorobenzylidene)-2,5-difluorobenzohydrazide 
• 1459280-46-6 (E)-N’-(2,4-dimethoxybenzylidene)-2,5-difluorobenzohydrazide 
• 1459280-47-7 (E)-N’-(2,5-dimethoxybenzylidene)-2,5-difluorobenzohydrazide 
• 1459280-48-8 (E)-N’-(3,4,5-trimethoxybenzylidene)-2,5-difluorobenzohydrazide 
• 800406-59-1 (E)-N'-(benzofuran-2-yl)methylene-2,5-difluorobenzohydrazide 
• 1459280-38-6 (E)-N'-(benzylidene)-2,5-difluorobenzohydrazide 
• 1459280-39-7 (E)-N'-(4-fluorobenzylidene)-2,5-difluorobenzohydrazide 
• 1459280-40-0 (E)-N'-(4-bromobenzylidene)-2,5-difluorobenzohydrazide 

Relevant academic research and scientific papers

Synthesis and anti-inflammatory activity of hydrazide-hydrazones bearing anacardic acid and 1,2,3-triazole ring based hybrids

A novel series of hydrazide-hydrazone derivatives 39-50, linked with anacardic acid motif and 1,2,3-triazole ring were synthesized by reacting 4-(1-(2-methoxy-6-pentadecylbenzyl)-1H-1, 2, 3-triazol-4-yl)benzaldehyde with 2-phenyl-acetohydrazides and benzohydrazides. The structures of the newly synthesized hydrazide-hydrazone derivatives 39-50 were confirmed by 1H NMR, MS and IR spectroscopic tools. These compounds were also evaluated for their anti-inflammatory activity by carrageenan paw edema method.

Synthesis of novel benzohydrazides bearing 4-[3-methyl-4-(methylsulfonyl)pyridin-2-yl] moiety as potential antibacterial agents

This work reports the synthesis and antibacterial activity of novel hydrazone derivatives 8a-k bearing 4-[3-methyl-4-(methylsulfonyl)pyridin- 2-yl] moiety. Spectroscopic techniques like 1H NMR, mass and IR tools was utilized for the characterization of these hydrazone derivatives. The synthesized hydrazone derivatives were tested against a set of bacterial strains, namely, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus pyogenes by paper disc diffusion method. Compounds 8b, 8d, 8e, 8f, 8h, 8i showed good antibacterial activity against the test organisms.

Synthesis, characterization and antimicrobial evaluation of novel (E)-N′-(4-(1-((3,4-dimethoxypyridin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)benzylidene)benzohydrazide derivatives

The synthesis of novel 1,2,3-triazole-hydrazone derivatives embedded with 3,4-dimethoxy pyridine ring nucleus is described. These derivatives were prepared utilizing, 2-(chloromethyl)-3,4-dimethoxypyridine 1, 4-ethynylbenzaldehye 5 and various benzohydrazides7a-7j. The structures of the newly synthesized 1,2,3-triazole-hydrazones 8a-j was established on the basis of the spectroscopic techniques like 1H NMR, mass and IR data. They were evaluated against a panel of bacterial and fungal pathogens such as Staphylococcus. pyogens, Staphylococcus. Aureus (Gram positive bacteria), Escherichia.coli, Pseudomonas. aeruginosa (Gram negative bacteria) and Aspergillus niger and Candida albicans (Fungal stains). Compounds 8b, 8c, 8d, 8e and 8f with R = 4-OH, 4-OMe, 4-SO2Me, 3,45,-OMe and 3-NO2 respectively showed moderate antibacterial activity while compounds 8b, 8d, 8i and 8j with R = 4-OH, 4-SO2Me, 3,5-dichloro and 2,5-difluoro substitution exhibited very good fungal activity.

Synthesis and antibacterial activity of some new quinaxaline-benzohydrazides

Quinoxalines have been found to exhibit various biological activities such as antibacterial, antifungal, anti-tubercular, anxiolytic, anticancer, antioxidant, anti-inflammatory, anti-HIV, antihelmintic and anticonvulsant. The present study aims towards synthesis, characterization and determination of antimicrobial susceptibility testing of various novel quinoxaline derivatives. The quinoxaline-benzohydrazides 6a-m have been obtained by the condensation of quinoxaline-2-carboxaldehyde 4 with various benzohydrazides 5a-m in ethanol at reflux temperature. All the newly synthesized quinoxaline-benzohydrazide derivatives have been characterized by 1H NMR, IR and mass spectroscopic analysis. The synthesized quinoxaline-benzohydrazides 6a-m have been screened for antibacterial activity. Most of the compounds show significant antibacterial activity.

Synthesis and antimicrobial activity of new imidazole-hydrazone derivatives

Hydrazones demonstrated significant antimicrobial activity, antitubercular activity and antitumoral activity in medicinal areas. The imidazole nucleus is well known to play an important role in living organisms since it is incorporated into the histidine molecule and many other important biological, pharmacological and therapeutic activities. Condensation of 4-phenyl-1H-imidazole-2-carbaldehyde (3) with various selected benzohydrazides (4a-m) resulted in imidazole-hydrazone derivatives (5a-m). They were evaluated for antibacterial and antifungal activity against A. Niger, C. albicans (fungal strains), E. coli and P. aeruginosa (Gram-negative bacteria), S. aureus and S. pyogenes (Gram-positive bacteria) using griseofluvin (for fungi) and ciprofloxacin (for bacteria) as the standard drugs. In general, it is observed that most of the compounds were found to be potent against both the bacterial and fungal strains.

Synthesis of novel hydrazone derivatives of 2, 5-difluorobenzoic acid as potential antibacterial agents

Hydrazones are important classes of compounds found in many synthetic products. Due to their importance in synthetic chemistry, the present article reports the synthesis of twelve new hydrazone derivatives based on the coupling of 2,5-difluorobenzohydrazi

SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS

The present invention is related to heterocycles represented by a compound of Formula (I) that are novel allosteric modulators of α7 nAChRs and/or GABAA receptors. The invention also discloses the treatment of disorders that are responsive to e

SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS

The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising thes

SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY

The present invention relates to compounds of Formula (I), below, (wherein X, R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising t

COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY

The present invention relates to compounds of Formula (I), below, (wherein R1, R2, R3, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically accepta